Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations

J. L. Juncos, G. Fabbrini, M. M. Mouradian, T. N. Chase

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Parkinsonian patients receiving long-term levodopa-carbidopa (Sinemet) therapy often develop fluctuations in motor performance. Although maintenance of stable levels of plasma levodopa by means of its continuous intravenous infusion diminishes these fluctuations, practical limitations attending this therapeutic approach have prompted continuing attempts to develop oral controlled release levodopa-carbidopa formulations. In a double-blind, crossover clinical trial, one such preparation, CR-5 (Merck, Sharp & Dohme), produced significantly less plasma levodopa variations and substantially improved motor performance over Sinemet in 15 patients with mild to moderate fluctuations, all but one of whom chose to continue on CR-5 therapy after the study. Eight patients with severe motor fluctuations could not adjust to this preparation during the open phase and consequently withdrew from the study. Subjectively, most patients noted the convenience of less frequent dosing, improved sleep, and the amelioration of early morning akinesia and dystonia.

Original languageEnglish
Pages (from-to)1010-1012
Number of pages3
JournalArchives of Neurology
Volume44
Issue number10
DOIs
Publication statusPublished - 1987

Fingerprint

Levodopa
Dystonia
Intravenous Infusions
Cross-Over Studies
Sleep
Therapeutics
Maintenance
Clinical Trials
levodopa drug combination carbidopa
Controlled
Fluctuations
Plasma
Therapy

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations. / Juncos, J. L.; Fabbrini, G.; Mouradian, M. M.; Chase, T. N.

In: Archives of Neurology, Vol. 44, No. 10, 1987, p. 1010-1012.

Research output: Contribution to journalArticle

Juncos, J. L. ; Fabbrini, G. ; Mouradian, M. M. ; Chase, T. N. / Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations. In: Archives of Neurology. 1987 ; Vol. 44, No. 10. pp. 1010-1012.
@article{72165455b4a34a3f917a20cb26860514,
title = "Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations",
abstract = "Parkinsonian patients receiving long-term levodopa-carbidopa (Sinemet) therapy often develop fluctuations in motor performance. Although maintenance of stable levels of plasma levodopa by means of its continuous intravenous infusion diminishes these fluctuations, practical limitations attending this therapeutic approach have prompted continuing attempts to develop oral controlled release levodopa-carbidopa formulations. In a double-blind, crossover clinical trial, one such preparation, CR-5 (Merck, Sharp & Dohme), produced significantly less plasma levodopa variations and substantially improved motor performance over Sinemet in 15 patients with mild to moderate fluctuations, all but one of whom chose to continue on CR-5 therapy after the study. Eight patients with severe motor fluctuations could not adjust to this preparation during the open phase and consequently withdrew from the study. Subjectively, most patients noted the convenience of less frequent dosing, improved sleep, and the amelioration of early morning akinesia and dystonia.",
author = "Juncos, {J. L.} and G. Fabbrini and Mouradian, {M. M.} and Chase, {T. N.}",
year = "1987",
doi = "10.1001/archneur.1987.00520220016008",
language = "English",
volume = "44",
pages = "1010--1012",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations

AU - Juncos, J. L.

AU - Fabbrini, G.

AU - Mouradian, M. M.

AU - Chase, T. N.

PY - 1987

Y1 - 1987

N2 - Parkinsonian patients receiving long-term levodopa-carbidopa (Sinemet) therapy often develop fluctuations in motor performance. Although maintenance of stable levels of plasma levodopa by means of its continuous intravenous infusion diminishes these fluctuations, practical limitations attending this therapeutic approach have prompted continuing attempts to develop oral controlled release levodopa-carbidopa formulations. In a double-blind, crossover clinical trial, one such preparation, CR-5 (Merck, Sharp & Dohme), produced significantly less plasma levodopa variations and substantially improved motor performance over Sinemet in 15 patients with mild to moderate fluctuations, all but one of whom chose to continue on CR-5 therapy after the study. Eight patients with severe motor fluctuations could not adjust to this preparation during the open phase and consequently withdrew from the study. Subjectively, most patients noted the convenience of less frequent dosing, improved sleep, and the amelioration of early morning akinesia and dystonia.

AB - Parkinsonian patients receiving long-term levodopa-carbidopa (Sinemet) therapy often develop fluctuations in motor performance. Although maintenance of stable levels of plasma levodopa by means of its continuous intravenous infusion diminishes these fluctuations, practical limitations attending this therapeutic approach have prompted continuing attempts to develop oral controlled release levodopa-carbidopa formulations. In a double-blind, crossover clinical trial, one such preparation, CR-5 (Merck, Sharp & Dohme), produced significantly less plasma levodopa variations and substantially improved motor performance over Sinemet in 15 patients with mild to moderate fluctuations, all but one of whom chose to continue on CR-5 therapy after the study. Eight patients with severe motor fluctuations could not adjust to this preparation during the open phase and consequently withdrew from the study. Subjectively, most patients noted the convenience of less frequent dosing, improved sleep, and the amelioration of early morning akinesia and dystonia.

UR - http://www.scopus.com/inward/record.url?scp=0023428710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023428710&partnerID=8YFLogxK

U2 - 10.1001/archneur.1987.00520220016008

DO - 10.1001/archneur.1987.00520220016008

M3 - Article

VL - 44

SP - 1010

EP - 1012

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 10

ER -